BENGALURU, Oct 22 (Reuters) - A data breach at Dr Reddy's
Laboratories Ltd prompted the Indian drugmaker to shut
its key plants globally, television channel ET Now reported on
Thursday, citing sources.
Shares of the company, which has a partnership to run
clinical trials of Russia's Sputnik-V COVID-19 vaccine in India,
fell as much as 4.3% on the news, dragging the Nifty pharma
sub-index down 2%.
The data breach occurred at servers of the company and
plants in the United States, United Kingdom, Brazil, India and
Russia were impacted, the ET Now report said.
Dr Reddy's did not immediately respond to Reuters' queries.
The Russian Direct Investment Fund (RDIF) and Dr Reddy's got
renewed approval to conduct late-stage clinical trials in India
for the Sputnik-V vaccine after the country's regulator had
earlier asked them to conduct a smaller trial.
(Reporting by Nallur Sethuraman in Bengaluru; Editing by Sriraj